We are live on ! Find out more
LC

Lindbrook Capital Portfolio holdings

AUM $1.08B
1-Year Est. Return 10.14%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+10.14%
3 Year Est. Return
+35.77%
5 Year Est. Return
+141.26%
10 Year Est. Return
AUM
$1.06B
AUM Growth
-$4.21M
Cap. Flow
-$36.2M
Cap. Flow %
-3.4%
Top 10 Hldgs %
45.51%
Holding
2,874
New
227
Increased
1,384
Reduced
630
Closed
115

Top Sells

Rank Stock Value
1
OCSL icon
Oaktree Specialty Lending
OCSL
+$12.7M
2
NVDA icon
NVIDIA
NVDA
+$6.29M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.66M
4
AAPL icon
Apple
AAPL
+$3.19M
5
AVGO icon
Broadcom
AVGO
+$2.17M

Sector Composition

Rank Sector Weight
1 Technology 17.21%
2 Financials 12.25%
3 Healthcare 6.29%
4 Communication Services 4.39%
5 Consumer Discretionary 3.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CYH icon
2301
Community Health Systems
CYH
$400M
$2.32K ﹤0.01%
690
+151
+28% +$508
IMXI icon
2302
International Money Express
IMXI
$350M
$2.31K ﹤0.01%
111
ATNI icon
2303
ATN International
ATNI
$481M
$2.3K ﹤0.01%
101
+92
+1,022% +$2.24K
ARIS
2304
Aris Mining
ARIS
$3.58B
$2.3K ﹤0.01%
+612
New +$2.46K
FUBO icon
2305
FuboTV Inc
FUBO
$293M
$2.3K ﹤0.01%
154
-335
-69% -$5.36K
TALO icon
2306
Talos Energy
TALO
$2.6B
$2.28K ﹤0.01%
188
-144
-43% -$1.8K
KEUA
2307
DELISTED
KraneShares European Carbon Allowance Strategy ETF
KEUA
$2.28K ﹤0.01%
100
-800
-89% -$18.9K
ALGT icon
2308
Allegiant Air
ALGT
$2.37B
$2.26K ﹤0.01%
45
+15
+50% +$840
MIRM icon
2309
Mirum Pharmaceuticals
MIRM
$5.99B
$2.26K ﹤0.01%
66
+60
+1,000% +$1.57K
RNG icon
2310
RingCentral
RNG
$5.3B
$2.26K ﹤0.01%
80
+64
+400% +$2.06K
ALG icon
2311
Alamo Group
ALG
$2.07B
$2.25K ﹤0.01%
13
+3
+30% +$585
GLBE icon
2312
Global E Online
GLBE
$6.86B
$2.25K ﹤0.01%
+62
New +$2K
FORM icon
2313
FormFactor
FORM
$9.46B
$2.24K ﹤0.01%
37
CRAI icon
2314
CRA International
CRAI
$1.06B
$2.24K ﹤0.01%
13
HY icon
2315
Hyster-Yale Materials Handling
HY
$619M
$2.23K ﹤0.01%
32
-1
-3% -$68
TTGT icon
2316
TechTarget
TTGT
$271M
$2.21K ﹤0.01%
71
-138
-66% -$4.1K
GRAL
2317
GRAIL Inc
GRAL
$3.37B
$2.21K ﹤0.01%
+144
New +$2.34K
ORGO icon
2318
Organogenesis Holdings
ORGO
$243M
$2.19K ﹤0.01%
+781
New +$2.1K
LILA icon
2319
Liberty Latin America Class A
LILA
$1.68B
$2.18K ﹤0.01%
+334
New +$1.86K
QTRX icon
2320
Quanterix
QTRX
$124M
$2.18K ﹤0.01%
165
CPRX
2321
DELISTED
Catalyst Pharmaceutical
CPRX
$2.17K ﹤0.01%
140
+109
+352% +$1.7K
MIR icon
2322
Mirion Technologies
MIR
$3.8B
$2.17K ﹤0.01%
202
+41
+25% +$436
CDMO
2323
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$2.16K ﹤0.01%
303
+63
+26% +$482
UHAL icon
2324
U-Haul Holding Co
UHAL
$14.3B
$2.16K ﹤0.01%
35
+12
+52% +$781
AMPH icon
2325
Amphastar Pharmaceuticals
AMPH
$869M
$2.16K ﹤0.01%
54
-9
-14% -$373

Similar funds

Lindbrook Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Lindbrook Capital held 2,874 positions worth $1.06B, down 0.39% from $1.07B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Lindbrook Capital withdrew a net $36.2M in Q2 2024, closing 115 positions and reducing 630 holdings. Its most notable exit was ProShares UltraPro QQQ, an estimated $1.24M position sold in full.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Lindbrook Capital opened a new position in Nuveen ESG Small-Cap ETF worth $323K.

  • Lindbrook Capital's largest Q2 2024 buy was Nuveen ESG Small-Cap ETF: 8,216 shares worth $323K.
  • Lindbrook Capital added most to State Street SPDR S&P 500 ETF Trust in Q2 2024, an estimated $3.36M increase.
  • Lindbrook Capital's biggest Q2 2024 reduction was Oaktree Specialty Lending, cutting an estimated $12.7M.
  • Lindbrook Capital fully exited ProShares UltraPro QQQ in Q2 2024, selling an estimated $1.24M.
  • Lindbrook Capital's ten largest holdings make up 46% of its $1.06B portfolio in Q2 2024.
  • Lindbrook Capital opened 227 new positions and closed 115 in Q2 2024.
  • Lindbrook Capital's portfolio value fell 0.39% quarter-over-quarter to $1.06B.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.